Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis

OP0169 Sarilumab for the treatment of ankylosing spondylitis: Results of a phase 2, randomized. Double-blind, placebo-controlled, international study (align)

(2014) J. Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Value of high-sensitivity C-reactive protein for classification of early axial spondyloarthritis: results from the DESIR cohort

(2013) Victoria Navarro-Compán et al.   ANNALS OF THE RHEUMATIC DISEASES

Fast relapse upon discontinuation of tumour necrosis factor blocking therapy in patients with peripheral spondyloarthritis

(2013) Jacqueline E Paramarta et al.   ANNALS OF THE RHEUMATIC DISEASES

Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials

(2013) Joachim Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial

(2013) Dominique Baeten et al.   LANCET

S100A8 and S100A9: DAMPs at the Crossroads between Innate Immunity, Traditional Risk Factors, and Cardiovascular Disease

(2013) Alexandru Schiopu et al.   MEDIATORS OF INFLAMMATION

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)

(2012) Joachim Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Anti-TNF treatment blocks the induction of T cell-dependent humoral responses

(2012) Gabriela Franco Salinas et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis

(2012) Jacqueline E Paramarta et al.   ANNALS OF THE RHEUMATIC DISEASES

ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNF  inhibitors

(2011) S. J. Pedersen et al.   ANNALS OF THE RHEUMATIC DISEASES

Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis

(2011) Denis Poddubnyy et al.   ARTHRITIS AND RHEUMATISM

Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis

(2010) D. Poddubnyy et al.   ANNALS OF THE RHEUMATIC DISEASES

Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors

(2010) Susanne Juhl Pedersen et al.   CLINICAL RHEUMATOLOGY

Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid A protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis

(2009) Mirjam K. de Vries et al.   ARTHRITIS AND RHEUMATISM

Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs' treatment effect on C-reactive protein

(2009) M. Benhamou et al.   RHEUMATOLOGY

From gene expression to serum proteins: biomarker discovery in ankylosing spondylitis

(2008) N Haroon et al.   ANNALS OF THE RHEUMATIC DISEASES

Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis

(2008) C Lukas et al.   ANNALS OF THE RHEUMATIC DISEASES

Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis

(2008) Désirée van der Heijde et al.   ARTHRITIS AND RHEUMATISM

Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease

(2008) D Foell et al.   JOURNAL OF PATHOLOGY

Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment

(2008) Heiner Appel et al.   ARTHRITIS RESEARCH & THERAPY